Results 11 to 20 of about 7,521 (213)

Artificial neural network accurately predicts hepatitis B surface antigen seroclearance. [PDF]

PLoS ONE, 2014
Background & aimsHepatitis B surface antigen (HBsAg) seroclearance and seroconversion are regarded as favorable outcomes of chronic hepatitis B (CHB).
Ming-Hua Zheng, Wai-Kay Seto, Ke-Qing Shi, Danny Ka-Ho Wong, James Fung, Ivan Fan-Ngai Hung, Daniel Yee-Tak Fong, John Chi-Hang Yuen, Teresa Tong, Ching-Lung Lai, Man-Fung Yuen   +10 more
doaj   +3 more sources

Serum Hepatitis B Virus RNA Levels Predict HBeAg Seroconversion and Virological Response in Chronic Hepatitis B Patients with High Viral Load Treated with Nucleos(t)ide Analog [PDF]

Infection and Drug Resistance, 2020
Xin Ji,* Muye Xia,* Bin Zhou, Shi Liu, GuiChan Liao, Shaohang Cai, Xiaoyong Zhang, Jie Peng State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang ...
Ji X, Xia M, Zhou B, Liu S, Liao G, Cai S, Zhang X, Peng J   +7 more
doaj   +2 more sources

Hepatitis B virus RNA and hepatitis B surface antigen kinetics predict treatment outcomes in children with chronic hepatitis B [PDF]

Frontiers in Cellular and Infection Microbiology
BackgroundSerum hepatitis B virus (HBV) pregenomic RNA (pgRNA) predicts antiviral response in adults with chronic hepatitis B (CHB); however, its prognostic performance against conventional biomarkers in children remains underexplored.
Xiaorong Peng, Yunan Chang, Jiaying Wu, Jing Zhu, Peng Hu, Hong Ren, Hongmei Xu, Ruiqiu Zhao, Tao Qin   +8 more
doaj   +2 more sources

Prevalence and clinical significance of HBeAg-positive chronic hepatitis B patients with and without anti-HBe antibody [PDF]

Virulence
The clinical significance of the coexistence of hepatitis B e antigen (HBeAg) and antibodies against HBeAg (anti-HBe) in patients with chronic hepatitis B (CHB) remains unclear.
Ruifei Xue, Jian Wang, Jie Zhan, Zhiyi Zhang, Suling Jiang, Jiacheng Liu, Li Wang, Xiaomin Yan, Shengxia Yin, Xin Tong, Weimao Ding, Jie Li, Yuxin Chen, Rui Huang, Chao Wu   +14 more
doaj   +2 more sources

Antiviral treatment response to nucleos(t)ide analogues in chronic hepatitis B patients with normal alanine aminotransferase levels: a retrospective multi-center study [PDF]

Emerging Microbes and Infections
Background: Whether patients with chronic hepatitis B (CHB) with normal alanine aminotransferase (ALT) levels should receive antiviral therapy remains controversial.
Fei Cao, Jian Wang, Ye Xiong, Ying Zhang, Xinrong Zhang, Tao Fan, Li Zhu, Shaoqiu Zhang, Zhiyi Zhang, Yifan Pan, Yuanyuan Li, Chao Jiang, Juan Xia, Yu Shi, Xiaomin Yan, Yuxin Chen, Xingxiang Liu, Chuanwu Zhu, Chao Wu, Rui Huang   +19 more
doaj   +2 more sources

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b

Chinese Medical Journal, 2016
Background: We aimed to evaluate the usefulness of serum hepatitis B virus core-related antigens (HBcrAg) for predicting hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients treated with conventional interferon (IFN)
Hui Ma, Rui-Feng Yang, Xiao-He Li, Qian Jin, Lai Wei   +4 more
doaj   +3 more sources

HBV RNA at 6 months after nucleos(t)ide analogues treatment can predict antiviral efficacy in chronic hepatitis B patients [PDF]

BMC Gastroenterology
Background This multicenter study evaluated serum HBV RNA as a prognostic biomarker for nucleos(t)ide analogue (NA) therapy in chronic hepatitis B (CHB), focusing on correlations with HBV DNA/HBsAg and predictive value for virological response (VR) and ...
Yandi Xie, Xiaojing Zhang, Xiaozhou Yang, Sujun Zheng, Shuyun Zhang, Xiaoying Zhang, Haiyan Kang, Xuefei Duan, Wenpin Cai, Peng Yin, Xinghuan Ma, Juan liu, Fengmin Lu, Lizhong Dai, Bo Feng   +14 more
doaj   +2 more sources

Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters

JHEP Reports, 2021
Summary: Background & Aims: We aimed to investigate how viral quasispecies of the HBV whole genome evolves and diversifies in response to HBeAg seroconversion and viral control utilising next-generation sequencing (NGS).
Su-Ru Lin, Ta-Yu Yang, Cheng-Yuan Peng, You-Yu Lin, Chia-Yen Dai, Hurng-Yi Wang, Tung-Hung Su, Tai-Chung Tseng, I-Jung Liu, Huei-Ru Cheng, Yueh-Chi Shen, Fang-Yi Wu, Chun-Jen Liu, Ding-Shinn Chen, Pei-Jer Chen, Hung-Chih Yang, Jia-Horng Kao   +16 more
doaj   +1 more source

52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic Hepatitis B [PDF]

, 2013
Background and Aims: The Roadmap concept is a therapeutic framework in chronic hepatitis B for the intensification of nucleoside analogue monotherapy based on early virologic response.
Aldo Trylesinski, AS Levey, AS Lok, BJ McMahon, CJ Chen, CL Lai, DJ Tenney, DJ Tenney, DW Cockcroft, EB Keeffe, Eduardo Fassio, Fernando Bessone, H Izzedine, H Mommeja-Marin, H Yang, Henry L. Y. Chan, HL Chan, Hugo Cheinquer, Javier R. Lama, JD Jia, Jorge Daruich, KL Andersson, Liver European Association For The Study Of The, MF Yuen, MF Yuen, Mário G. Pessôa, N Leung, P Marcellin, Piyawat Komolmit, Rashidkhan Pathan, RD Cooper, RG Gish, S Mauss, S Zeuzem, Stefan Zeuzem, Suzane K. Ono, Tawesak Tanwandee, Teerha Piratvisuth, Wattana Sukeepaisarnjaroen, YF Liaw, YF Liaw, Yuhong Dong   +41 more
core   +9 more sources

Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression? [PDF]

, 2006
The availability of nucleoside analogues has broadened treatment options for chronic hepatitis B virus (HBV ) infection. Registered treatment for chronic hepatitis B currently consists of (pegylated) interferon, lamivudine and adefovir,
Buster, E.H.C.J. (Erik), Janssen, H.L.A. (Harry)   +1 more
core   +11 more sources